Jpmorgan Chase & CO Clene Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.33 - $73.0 $21,286 - $4.71 Million	-64,504 Reduced 99.98%	15 $0
Q2 2022 Aug 11, 2022	BUY	$2.1 - $4.12 $115,273 - $226,155	54,892 Added 570.19%	64,519 $163,000
Q1 2022 May 11, 2022	BUY	$2.42 - $4.42 $5,031 - $9,189	2,079 Added 27.54%	9,627 $38,000
Q4 2021 Feb 10, 2022	SELL	$3.95 - $7.53 $9,499 - $18,109	-2,405 Reduced 24.16%	7,548 $31,000
Q3 2021 Nov 12, 2021	BUY	$6.83 - $13.58 $67,978 - $135,161	9,953 New	9,953 $67,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $273M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.